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Abstract 
Introduction 
Laboratory studies suggest adrenergic blockers may inhibit the proliferation and 
migration of cancer cells, but epidemiological evidence of their effect on cancer 
incidence has proved inconsistent. We therefore conducted a case-control study using 
the Clinical Practice Research Datalink to assess the effect of adrenergic blockers 
upon incidence of prostate, lung, bowel and breast cancer. 
Methods 
Amongst patients aged 18 years or older contributing at least 2 years of prospectively 
gathered data between 01/01/1987 – 31/12/2012, we selected incident cases of 
relevant cancers and controls, frequency matched 10:1 by age. Logistic regression was 
used to adjust effect estimates for age, sex, smoking, alcohol use, and a number of 
potentially confounding co-morbidities and co-prescriptions.  
Results 
18968 colorectal, 19082 lung, 21608 prostate and 29109 breast cancers were 
identified. We found no evidence of a protective effect of adrenergic blockade in lung 
and prostate cancer and found a slightly increased risk of colorectal and breast cancers 
in users. This was largely explained by the effects of confounding in a multivariate 
analyses with final OR estimates of lung, colorectal, breast and prostate cancer of 0.99, 
95% CI [0.96-1.04]1.14, [1.09 – 1.18]1.10, [1.06 – 1.14]1.01, [0.98-1.05] respectively 
for beta blocker exposure and 1.03, [0.97 – 1.09]1.13, [1.07 – 1.20]1.08, [1.00 – 1.17] 
for alpha blocker exposure.  
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Conclusion 
We found no evidence to suggest that adrenergic blocker use prevents common 
cancers. Indeed, we found a slight increased risk of colorectal and breast cancer which 
may reflect residual confounding. 
 
Keywords: adrenergic blockers; Clinical Practice Research Datalink; prostate cancer; 
lung cancer; colorectal cancer; breast cancer   
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Introduction  
Progress in developing treatments for cancer remains slow thus alternative strategies 
for drug development such as repurposing previously approved drugs are being 
considered (Pasquier, Ciccolini et al. 2011). This strategy may reduce risks, costs and 
time required in drug development (Pasquier, Ciccolini et al. 2011). A specific example 
of this is the potential anti-neoplastic effects of aspirin with a near 50% reduction in 
cancer specific mortality from colorectal cancer recently shown in those starting aspirin 
after diagnosis (Chan, Ogino et al. 2009), which has already led to a randomised 
controlled trial (Ali, Toh et al. 2011).   
Laboratory studies of both beta- and alpha-blockers have shown that by blocking 
adrenergic signalling they inhibit both stimulation of growth and migratory activity of 
tumour cells by these neurotransmitters (Masur, Niggemann et al. 2001; Benning and 
Kyprianou 2002; Drell IV, Joseph et al. 2003; Foster, Yono et al. 2004; Lang, Drell IV et 
al. 2004; Palm, Lang et al. 2006; Sood, Bhatty et al. 2006; Hui, Fernando et al. 2008; 
Al-Wadei, Al-Wadei et al. 2009; Sakamoto, Schwarze et al. 2011; Pasquier, Andre et 
al. 2013). Furthermore beta blockade is of proven efficacy in the treatment of infantile 
haemangiomas (Fuchsmann, Quintal et al. 2011; Xu, Lv et al. 2012). 
These encouraging results have led to a number of epidemiological studies on β-
blockers which have not shown a consistent beneficial effect in common cancers 
(González-Pérez, Ronquist et al. 2004; Perron, Bairati et al. 2004; Ronquist, Rodríguez 
et al. 2004; Algazi, Plu-Bureau et al. 2006; Rodriguez, Jacobs et al. 2009; Friedman, 
Udaltsova et al. 2011; Hallas, Christensen et al. 2012; Jansen, Below et al. 2012). Few 
epidemiological studies have been undertaken in alpha blockers but what evidence 
there is, is inconsistent. (Friedman, Udaltsova et al. 2011; Hallas, Christensen et al. 
2012). 
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Limited sample sizes and inadequate adjustment for confounders in some studies have 
possibly contributed to the differences in the results observed. To address this 
problem, we conducted a case-control study using data from the Clinical Practice 
Research Datalink (CPRD) database, a large population healthcare database to allow 
adjustment for relevant confounding variables. We investigated the 4 most common 
cancers in the UK; colorectal, lung, breast and prostate cancer (Statistics 2012) since 
laboratory studies have shown evidence of an anti-tumourigenic effects of adrenergic 
blockers upon them (Schuller and Cole 1989; Masur, Niggemann et al. 2001; Drell IV, 
Joseph et al. 2003) and CPRD provided adequate power to investigate each.  
Additionally, we have investigated the effect of differing doses and durations of 
adrenergic blocker use and the specificity of its effect by comparing results to those 
found with another class of agents sharing a number of its indications (calcium channel 
blockers). 
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Materials and Methods 
Setting 
The Clinical Practice Research Datalink (CPRD) contains anonymised computerised 
clinical information from over 600 general practices across the UK with the earliest 
records dating to 1987. These records include more than 11 million patients (Card, 
Siffledeen et al. 2014) making it the largest source of anonymised longitudinal data 
from primary care in the world (Khan, Harrison et al. 2010). Individual records include 
demographic information, clinical diagnoses, prescription and treatment details.  
Study Population 
We conducted a frequency matched case-control study of subjects during the period in 
which they contributed prospectively gathered data to CPRD from the period 
01/01/1987 – 31/12/2012 and occurring after the age of 18 and at least 2 years after 
they entered the dataset. Cases were defined by a first recorded medical diagnosis of 
lung, bowel, prostate or breast cancer in females. Controls were selected from 
contributing subjects with no recorded medical diagnosis of prostate, lung, bowel or 
breast cancer in their clinical record prior to a random date allocated (henceforth 
referred to as their pseudo-diagnosis date) and frequency matched by 10 year age 
bands in a ratio of 10:1 for each malignancy separately. In addition we limited control 
selection for breast cancer to females and for prostate cancer to males.   
Exposure and covariates 
Subjects with two or more prescriptions for alpha or beta blocker use within the 2 year 
window prior to diagnosis or pseudo-diagnosis were considered exposed. We then 
considered dose by determining the mean dose across all exposed days for each 
subject, and then dividing by the maximum recommended daily dose (of the individual 
adrenergic blocker used as determined by the BNF).  We used the median of the 
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standardised doses across a combination of the cancers under study to split subjects 
into high dose, low dose and unexposed categories. 
Age and sex were considered a priori confounders. Other potential confounders 
considered include smoking, alcohol use, co-morbidity (using the Charlson comorbidity 
Index as a composite measure (Charlson, Pompei et al. 1987), prophylactic 
medications (NSAID, statin and aspirin use), hormone replacement therapy and 
potential indications for use of the medications studied including ischaemic heart 
disease (IHD), heart failure (HF), hypertension, history of diabetes and benign prostatic 
hyperplasia and/or prostatism. Medication use was defined as two or more 
prescriptions for the specific medication within the 2 year window prior to diagnosis or 
pseudo-diagnosis. Co-morbidity and indication for use of the drug were assessed as 
any recordings of the variable prior to the date of diagnosis or pseudo-diagnosis. 
Charlson Index was a composite score of comorbidities categorised into none, 1 and 2. 
Age was calculated at diagnosis or pseudo-diagnosis date while BMI, smoking and 
alcohol were measured as the most recent recording of the variable prior to the 
diagnosis or pseudo-diagnosis date. Smoking status was categorised as non-smoker, 
current smoker, ex-smoker, missing; alcohol status as non-drinker, current drinker, 
problem-drinker and missing and BMI into 5 categories including missing. We created a 
missing category for all variables with missing data. 
Data Analysis 
We analysed data using logistic regression with univariable and subsequently 
multivariable analyses for each cancer under study with the resulting odds ratios and 
95% confidence intervals presented. Amongst the variables we extracted data for 
based on the plausibility of their confounding the relationship being studies, we 
determined potential confounders based on their association with the exposure and 
outcome and corroborated by similar studies conducted in this area. We built the 
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multivariable model by first including all possible confounders in the model and 
progressively removed confounders one at a time from the model in increasing 
importance that do not change the estimate of the effect of the primary exposure by at 
least 10%. We did this until none of the variables retained in the model could be 
removed without altering the effect estimate of the model significantly. At the end of 
each step of fitting the model, we repeated this process but instead progressively 
added the confounders one at a time to the model in decreasing importance to 
determine if included confounders remain significant in the model and removed 
confounders become significant in the model. We did this until we had only significant 
confounders present in the model.  
Sensitivity Analysis 
We assessed the effect of duration of adrenergic blocker use within a 10 year window 
prior to diagnosis or pseudo-diagnosis in a subset of subjects with 10 years of 
prospectively gathered data. We assessed the number of years of exposure of a 
subject starting with their diagnosis or pseudo-diagnosis date and looking at prior 
exposure back in time until their earliest exposure within this 10 year window. Subjects 
were considered exposed for those years in which they had at least one relevant 
prescription, and continuous exposure was considered to occur for the number of 
consecutive years in which subjects were exposed counting backwards from the 
diagnosis or pseudo-diagnosis date.  
Further Analysis 
 Finally we repeated all analyses substituting calcium channel blockers as the 
exposure. All analyses were conducted in Stata 12 [College Station, TX, USA.] 
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Results 
We identified 18968 cases of colorectal cancer (46% women), 19082 cases of lung 
cancer (42% women), 21608 cases of prostate cancer and 29109 cases of breast 
cancer. Supplementary table 1 shows the age distribution of cases and their age-
matched controls.  
 
Cancer cases were more likely to be current drinkers and had more comorbidities and 
hypertension than their respective controls (Table 1). In addition, Lung cancer cases 
had more current and ex-smokers and a higher level of aspirin and statin use than their 
controls. There were also a smaller proportion of missing data for smoking, alcohol and 
BMI cases compared to their respective controls for all cancers (Table 1). All other 
variables were similarly distributed in cases and controls. 
 
Cancer cases had more adrenergic blocker use than controls (Table 2).  Univariable 
analysis showed a significant positive association between both alpha and beta blocker 
exposure and all cancers. (Table 2) After adjustment for confounders we observed no 
effect of betablocker use on the risk of prostate cancer (OR: 1.01, 95% CI [0.98 – 
1.05]) and lung cancer 0.99 [0.96 – 1.04]) and similarly no effect of alphablocker use on 
the risk of breast cancer 1.08 [1.00 – 1.17] and lung cancer 1.03 [0.97 – 1.09] 
compared to non-use. A weak positive association remained between betablocker use 
and colorectal cancer 1.14 [1.09 – 1.18] breast cancer 1.10 [1.06 – 1.14] and similarly 
between alphablocker use and colorectal cancer 1.13 [1.07 – 1.20]. (Table 2) 
For calcium channel blockers similar patterns of effect to betablockers were observed 
in colorectal, breast and lung cancer in the multivariable analysis, though in prostate 
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cancer 1.14 [1.10 – 1.18]  a slight increased risk was observed with calcium blocker 
exposure. (Supplementary table 2) 
 
Analysis by dose  
We found no clear evidence of differences in cancer risk with variations in dose. 
Though point estimates did vary by dose, changes were small and confidence intervals 
overlapped. Further details of adrenergic blocker use by dose are shown below (Table 
3) 
Analysis of duration in those with prolonged data 
We found no significant effects on cancer risk from regular long-term adrenergic 
blocker use in the subset of subjects with more prolonged data availability (Table 4).  
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Discussion 
In this large case-control study we found no effect of betablocker exposure in the 2 
year period prior to cancer diagnosis on the risk of lung or prostate cancer and a slight 
increase on the risk of colorectal and breast cancer. Alphablocker exposure showed no 
effect on the risk of breast and prostate cancer and a slight increase in the risk of 
colorectal cancer. Analysis by dose and long term exposure showed no clear dose or 
temporal effect for adrenergic blocker use on cancer risk. 
Study strengths and limitations 
This study is from a large primary care database representative of the UK population 
(Herrett, Thomas et al. 2010) and as data collection within the CPRD is prospective, 
information bias due to recall will be minimised. In addition, we were able to adjust for a 
number of important confounders including alcohol status, smoking status, BMI, 
medication use and comorbidities.  
A major limitation is our inability to individually validate cancer diagnoses and a 
potential therefore for misclassification. However, given the previously demonstrated 
high levels of specificity for diagnoses in these data i.e 99% of neoplasms (Dregan, 
Moller et al. 2012) we do not believe this will have greatly influenced our study.  
Our analyses confirm the presence of appreciable confounding in the relationships we 
have studied, but as we lack data on some potential confounders such as family 
history, diet and exercise it is likely that residual confounding will remain. 
Another potential limitation is missing data for confounding factors both by over the 
counter medication use (primarily NSAIDS and aspirin) and by lifestyle factors with a 
smaller proportion of missing data observed for smoking, alcohol and BMI cases 
compared to their respective control. It is likely that these data will not be missing at 
random, and instead due to variations in medical records consequent upon variation in 
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comorbidities or the frequency of physician visits. We have attempted to minimise this 
potential information bias by including missing as a separate category in the analysis 
for alcohol use, smoking and BMI. The potential for some information bias and 
likelihood of residual confounding remains however.  
Another potential bias is the possibility that those who are prescribed anti-
hypertensives, due to their increased contact with health services, are more likely to 
have an early cancer diagnosed. This bias cannot be entirely overcome, but since the 
same mechanism might be expected to increase prescription of other drugs used for 
similar indications we analysed calcium channel blockers. The results of the effect of 
calcium blockers were similar to those of betablockers and as these have different 
mechanisms of action it is unlikely the results seen in betablocker use reflect the effect 
of the drug but instead suggests bias by healthcare seeking behaviour.  
Our primary analysis restricted the assessment of adrenergic blocker use to the 
presence of 2 prescriptions within 2 years. It is possible that these criteria did not 
adequately reflect exposure as we have no data on adherence to treatment and results 
could instead represent low dose of adrenergic drug use. We therefore analysed the 
dose of adrenergic blocker use. Since minimal effects were seen with varying dose, we 
do not think that these issues are likely to invalidate our primary analysis. 
Furthermore, it is possible that the time window of 2 years represents insufficiently 
prolonged exposure to see a therapeutic effect on the occurrence of cancer, and a 
longer exposure period may be required. We therefore examined the effect of a longer 
duration of exposure in a subset of subjects that had up to 10 years of data prior to 
diagnosis or pseudo diagnosis date. These results did not alter our effect estimates 
and as a result we believe that a longer duration of adrenergic blocker exposure does 
not have a greater effect on the risk of cancer.  
Comparison with other studies 
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Previous studies have examined betablocker use and the incidence of colorectal 
(Friedman, Udaltsova et al. 2011; Jansen, Below et al. 2012) prostate (Perron, Bairati 
et al. 2004; Ronquist, Rodríguez et al. 2004; Rodriguez, Jacobs et al. 2009; Friedman, 
Udaltsova et al. 2011)  breast (González-Pérez, Ronquist et al. 2004; Fryzek, Poulsen 
et al. 2006; Friedman, Udaltsova et al. 2011) lung (Friedman, Udaltsova et al. 2011) 
and all cancers (Algazi, Plu-Bureau et al. 2006; Friedman, Udaltsova et al. 2011; 
Hallas, Christensen et al. 2012). 
Some studies such as the matched case-control studies by Perron et al, utilised large 
clinical databases (Perron, Bairati et al. 2004) showing a reduced incidence of prostate 
cancer on betablocker exposure 0.86 [0.77-0.96] but only adjusted for the confounding 
factors of age, sex, aspirin use and recent medical contacts which differed from the 
results of our study.  
 Other studies considered betablocker use and cancer risk in sub-group analyses only 
and it is likely that these studies were underpowered to detect significant effects 
(González-Pérez, Ronquist et al. 2004; Fryzek, Poulsen et al. 2006; Rodriguez, Jacobs 
et al. 2009).  For instance, a nested case-control study by Gonazalez-Perez et al on 
antihypertensive use and breast cancer risk (González-Pérez, Ronquist et al. 2004) 
started with 3708 cases and 20000 controls but to examine adrenergic blocker use, 
duration of use was split into current use, past and no use and this resulted in a 
population of cases and controls with very small numbers for some levels of drug 
exposure. Results showed no statistically significant difference in breast cancer 
incidence for those patients on beta and alpha blocker use and differ from the results of 
our study on betablocker use (González-Pérez, Ronquist et al. 2004). 
The most convincing evidence from large population based studies was a case-control 
study by Ronquist et al in 2004 (Ronquist, Rodríguez et al. 2004), conducted using the 
CPRD database. This examined 1013 cases of prostate cancer and 10000 controls 
with adjustments for important confounders including smoking status, BMI and alcohol 
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use. Results showed no statistically significant difference between beta blocker users 
and non-users with an odds ratio of 0.8 [0.6-1.0] for current use and 1.1 [0.9-1.4] for 
past use compared to non-use and for alpha blocker use an odds ratio of 3.6 [2.8-4.6] 
for current use and 1.1 [0.8-1.7] for past use compared to non-use. As we have used 
the same data source, though a larger and more recent version of it than in this study, 
it is reassuring that we find similar results. We have however expanded upon this study 
by including cancers of the breast, bowel and lung and within this investigated the dose 
and duration of use as well as the indication of use and can therefore provide more 
extensive information on the effect of adrenergic blocker exposure on the risk of 
cancer.  
 
Interpretation 
In this study we find no effect in some cancers or a weakly positive association of 
adrenergic blockade in others, contrary to what might be expected based on evidence 
from laboratory studies. It is possible that a higher concentration of adrenergic blockers 
than that prescribed for cardiovascular indications are needed to reproduce the pro-
apoptotic effects observed in these laboratory models. Also, several preclinical studies 
propose that downstream beta adrenergic effects are mediated mainly by the β2 or β3 
adrenergic receptors (E, M et al. 2006; Thaker, Han et al. 2006). As β1-selective beta 
blockers are more commonly prescribed for cardiovascular therapy, we were unable to 
look at the non-selective beta blocker subgroup for a beneficial effect.  However, 
results are not strongly significant in any cancer under study and it is possible that the 
slight increase in cancer risk observed in some cancers and the associated small effect 
sizes represent residual confounding due to the limited or lack of data on potential 
confounders such as family history, diet and exercise. 
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Conclusion 
To our knowledge, this is the most comprehensive study to date of the effect of alpha 
and beta blocker use on the incidence of common cancers in the UK.  We found no 
significant association between adrenergic blocker use and a reduced incidence of 
cancer and our finding of no consistent dose-response, temporal relationship or 
specificity of effect (compared to calcium channel blockers) mean we believe it more 
than likely that the slight increased risk observed in some cancers is as a result of 
residual confounding. However, an effect in specific beta blocker subgroups cannot be 
ruled out and further epidemiological research will require even larger epidemiological 
studies or pooled data to produce statistically robust results. This study using a large 
population database does not provide support for the hypothesis that adrenergic 
blocker use is associated with a reduced incidence of cancer.  
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